European Journal of Cancer
Volume 46, Issue 8 , Pages 1474-1480 , May 2010

A phase I clinical and pharmacokinetic study of paclitaxel liposome infused in non-small cell lung cancer patients with malignant pleural effusions

Received 16 August 2009 ,Revised 16 November 2009 ,Accepted 5 February 2010.

References 

  1. Fenton KN, Richardson JD. Diagnosis and management of malignant pleural effusions. Am J Surg. 1995;170(1):69–74
  2. Antony VB, Loddenkemper R, Astoul P, et al. Management of malignant pleural effusions. Eur Respir J. 2001;18(2):402–419
  3. Reeder LB. Malignant pleural effusions. Curr Treat Options Oncol. 2001;2:93–96
  4. Livingston RB, McCracken JD, Trauth CJ, Chen T. Isolated pleural effusion in small cell lung carcinoma: favorable prognosis. A review of the Southwest Oncology Group experience. Chest. 1982;81(2):208–211
  5. Marchi E, Teixeira LR, Vargas FS. Management of malignancy-associated pleural effusion: current and future treatment strategies. Am J Respir Med. 2003;2(3):261–273
  6. Walker-Renard PB, Vaughan LM, Sahn SA. Chemical pleurodesis for malignant pleural effusions. Ann Intern Med. 1994;120(1):56–64
  7. Rusch VW, Figlin R, Godwin D, Piantadosi S. Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions: a Lung Cancer Study Group trial. J Clin Oncol. 1991;9(2):313–319
  8. Perng RP, Chen YM, Wu MF, et al. Phase II trial of intrapleural paclitaxel injection for non-small-cell lung cancer patients with malignant pleural effusions. Respir Med. 1998;92(3):473–479
  9. Perng RP, Wu MF, Lin SY, Chen YM, Lin JY, Whang Peng J. A phase I feasibility and pharmacokinetic study of intrapleural paclitaxel in patients with malignant pleural effusions. Anti-Cancer Drugs. 1997;8(6):565–573
  10. Gilbar P, Ridge A. Dexamethasone prophylaxis for paclitaxel hypersensitivity. J Oncol Pharm Pract. 2002;8:81–87
  11. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649–655
  12. Markman M, Rowinsky E, Hakes T, et al. Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study. J Clin Oncol. 1992;10(9):1485–1491
  13. Murphy WK, Fossella FV, Winn RJ, et al. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst. 1993;85(5):384–388
  14. Chang AY, Kim K, Glick J, Anderson T, Karp D, Johnson D. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results. J Natl Cancer Inst. 1993;85(5):388–394
  15. Szebeni J, Muggia FM, Alving CR. Complement activation by cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst. 1998;90(4):300–306
  16. Drummond DC, Meyer O, Hong KL, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev. 1999;51(4):691–743

PII: S0959-8049(10)00105-X

doi: 10.1016/j.ejca.2010.02.002

European Journal of Cancer
Volume 46, Issue 8 , Pages 1474-1480 , May 2010

Article Tools

* Image Usage & Resolution